PensionDanmark Pensionsforsikringsaktieselskab Acquires 21,236 Shares of AbbVie Inc. $ABBV

PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 339,179 shares of the company’s stock after acquiring an additional 21,236 shares during the quarter. AbbVie comprises approximately 0.7% of PensionDanmark Pensionsforsikringsaktieselskab’s portfolio, making the stock its 22nd biggest holding. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in AbbVie were worth $85,351,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Mirabaud & Cie SA boosted its holdings in shares of AbbVie by 2.0% in the second quarter. Mirabaud & Cie SA now owns 8,766 shares of the company’s stock worth $2,206,000 after acquiring an additional 176 shares during the period. Mallini Complete Financial Planning LLC purchased a new stake in AbbVie during the 2nd quarter worth about $229,000. Assenagon Asset Management S.A. boosted its stake in AbbVie by 55.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,097,882 shares of the company’s stock worth $527,911,000 after purchasing an additional 748,838 shares during the period. Apella Capital LLC grew its holdings in AbbVie by 1.3% during the 2nd quarter. Apella Capital LLC now owns 20,565 shares of the company’s stock valued at $5,237,000 after buying an additional 267 shares in the last quarter. Finally, St. Louis Financial Planners Asset Management LLC purchased a new position in AbbVie during the 2nd quarter valued at about $5,013,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABBV. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $275.70.

AbbVie Trading Down 1.0%

Shares of AbbVie stock opened at $243.64 on Friday. The firm has a market capitalization of $430.46 billion, a PE ratio of 68.82, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The business’s 50-day moving average price is $241.40 and its 200-day moving average price is $224.82.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.